USA flag logo/image

An Official Website of the United States Government

DEVELOPMENT OF ROS KINASE INHIBITORS - PHASE I SBIR TOPIC 255

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96360
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
N43CO201000106
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
AUGUSTA PHARMACEUTICALS, INC.
58 OAK CLIFF RD NEWTONVILLE, MA 02460-
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: DEVELOPMENT OF ROS KINASE INHIBITORS - PHASE I SBIR TOPIC 255
Agency: HHS
Contract: N43CO201000106
Award Amount: $203,208.00
 

Abstract:

The Augusta founding laboratories have used cutting edge genetic technologies and shRNA screening methodologies to uncover the ROS receptor tyrosine kinase as a cancer survival gene. Studies from other laboratories have drawn a clear link between ROS kinase activity and the development and/or progression of astrocytic tumors such as glioblastoma, a grade IV astrocytoma, based on genetic findings, gene expression data, and animal models. Taken together, these findings validate a scientific rationale that links ROS kinase activity to glioblastoma metabolism and its associated patient morbidity and mortality. The overall objective of this proposal is to develop small molecules that inhibit the kinase activity of the ROS receptor tyrosine kinase for the primary indication of human glioblastoma multiforme (GBM). The specific objective of this proposal is to further develop prototype compounds using standard medicinal chemistry practices to generate more potent ROS inhibitors as judged by two approaches: 1) inhibition of enzymatic activity in vitro; and 2) selective growth inhibition of glioblastoma cells lines expressing aberrant ROS as compared to normal glial cells. If these criteria are satisfied, then we have validated a structurally optimized and biologically active molecule (i.e., a lead compound) that can be advanced to a Phase II program.

Principal Investigator:

Dorre Grueneberg
(713) 798-8167
Small Business Information at Submission:

AUGUSTA PHARMACEUTICALS, INC.
58 OAK CLIFF RD NEWTONVILLE, MA 02460-

EIN/Tax ID: 943444230
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No